Research

We intend to publish in depth articles showing our on-going research aims and results. This area is being developed and will be expanded on substantially, but as an interim measure we have prepared some extracts from our Cyclotron proposals briefing for your consideration.

Background

One of the key drivers for the Daisy Appeal's enthusiasm for developing fixed site PET-CT in Hull is the very significant potential it has for research. Being a relatively new technology there are significant opportunities on both the basic science and clinical fronts.

A substantial clinical need for new and improved biomarkers in PET imaging has been identified, but to realise this need a clear translational path is required to take basic science developments through to clinical use. Our aim is to set up a basic science research activity which will be linked with the clinical research to provide a direct pathway for translation of new biomarkers from design to synthesis to preclinical testing and then on through to patient trials.

In the study of PDG, we have identified a critical step for Hull to progress the technology - the use of microscale chemistry to produce new biomarkers. We propose to develop this novel technology funded by the Daisy Appeal in association with the cyclotron manufacturer.

Hull will be the only centre worldwide to combine a high level of expertise in microscale technology for synthesis and quality control validation with a cyclotron designed to produce both low dose and small volumes. This gives us a unique niche and potentially a position in the development of the next generation of PET technology.